

Properties affecting ARV dialysis clearance:

Drug	Molecular weight (daltons)	Protein binding (%)	Volume of Distribution L/kg	Extraction Ratio (%)	F _{HD} (%)	Primary elimination pathway
Nucleoside Reverse Transcriptase Inhibitors						
zidovudine	267.24	7-38	1.4-1.6	50-55	5-8	Hepatic metabolism
didanosine	236.23	<5	0.7-0.9	40-60	40	Renal excretion/hepatic met.
zalcitabine	211.22	<4	0.5-0.6	50	-	Renal excretion
stavudine	224.22	<10	0.5-1	68	-	Renal excretion/hepatic met.
lamivudine	229.30	<36	1.3	45-60	25	Renal excretion
emtricitibine	247.24	<4	1.4	-	30	Renal excretion
tenofovir	635.52	<0.7	1.2-1.3	54	10	Renal excretion
abacavir	670.76	10-13	0.8-1.9	24	10	Hepatic metabolism
Non-Nucleoside Reverse Transcriptase Inhibitors						
nevirapine	266.30	50-60	1.2-1.4	46.5	88	Hepatic metabolism
delavirdine	456.57	99	--	-	-	Hepatic metabolism
efavirenz	315.68	99-100	30	20	-	Hepatic metabolism
Protease Inhibitors						
ritonavir	720.95	>98	0.4	15.5	4	Hepatic metabolism
saquinavir	766.95	>98	3.6-10	2	4	Hepatic metabolism
indinavir	711.88	60	14	3	0	Hepatic metabolism
nelfinavir	663.90	>98	2-7	-	-	Hepatic metabolism
fosamprenavir	507.65	90	16.4	-	-	Hepatic metabolism
atazanavir	704.90	86	109L			

F_{HD} - Hemodialysis elimination of absorbed dose

References:

1. [An appraisal of antiretroviral drugs in hemodialysis. Kidney International, Vol. 60, 2001, pp. 821-830.](#)